Are Diageo plc, ReNeuron Group Plc & Persimmon plc On The Cusp Of Huge Returns?

Should you buy these 3 stocks right now? Diageo plc (LON: DGE), ReNeuron Group Plc (LON: RENE) and Persimmon plc (LON: PSN)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The house building sector continues to offer exceptionally good value for money. Evidence of this can be seen in Persimmon’s (LSE: PSN) valuation, with the company currently trading on a price to earnings (P/E) ratio of just 12.3. This indicates that there is considerable upward rerating potential on offer over the medium term even after Persimmon’s shares have soared by 418% in the last five years.

A potential catalyst to enable this to take place is upbeat earnings prospects. Persimmon is expected to increase its bottom line by 28% in the current financial year, with further growth of 10% being forecast for next year. This puts Persimmon on a price to earnings growth (PEG) ratio of just 1.2, which indicates that its shares offer high growth at a very reasonable price.

Looking further ahead, the UK has a chronic shortage of houses. Part of the reason for this is strict planning laws which mean that, while demand for housing remains high, their supply is unlikely to be boosted significantly in the next few years. And, while higher interest rates and buy-to-let tax changes will inevitably dampen demand and curtail the pace of house price growth, volumes are likely to remain buoyant for Persimmon and its peers. This should enable double-digit earnings growth to continue over the medium to long term.

Similarly, Diageo (LSE: DGE) also has considerable total return potential, with the beverages company offering a discounted valuation versus a number of its global consumer peers. Certainly, Diageo’s P/E ratio of 21 is hardly cheap when compared to many of its index peers, but with SABMiller having traded on a higher rating and still having been the subject of a bid from AB InBev, it shows that there is the potential for an upward rerating to Diageo’s valuation in future.

A potential catalyst for this is Diageo’s exposure to emerging markets. While they are currently underperforming, countries such as China and India hold vast potential when it comes to increasing demand from middle income earners for premium alcoholic drinks brands. With Diageo having a stable of such beverages, it could return to the double-digit earnings growth rates last experienced in 2012. And, with the outlook for Europe and the US being relatively upbeat for next year, Diageo’s wide geographical spread entails a high degree of consistency, too.

Meanwhile, it has been a very challenging year for biotech company ReNeuron (LSE: RENE), with its shares falling by 16% since the turn of the year. Looking ahead, its £70m fundraising from July appears to be sufficient to see it through a number of key clinical milestones, with it significantly strengthening the company’s balance sheet. And, with 2016 expected to be an important year for ReNeuron, with several of its ongoing clinical trials due to report, its shares could remain volatile over the next year.

While the company’s losses widened in its most recent set of results, it remains a company which has significant long term potential. However, with losses set to increase over the next couple of years, investor sentiment could weaken and put the company’s valuation under even greater pressure. Therefore, it may be prudent to watch, rather than buy, ReNeuron at the present time.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Persimmon. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

A top S&P 500 value share to consider as markets sell off!

Worried about the outlook for S&P 500 shares in the New Year? Buying value stocks like this tech giant is…

Read more »

Investing Articles

£20k of savings? Here’s how an investor could target £980 of passive income each month

With a £20k pot to deploy, our writer outlines how a long-term investor could target almost £1k a month in…

Read more »

Investing Articles

FTSE shares: a bargain way to start building wealth in 2025?

Christopher Ruane explains how, by buying FTSE 100 shares at what he thinks are bargain prices, he hopes to build…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

3 ISA mistakes to avoid in 2025

Our writer outlines a trio of mistakes investors can make in their ISA, to their cost, and explains why he’s…

Read more »

Older couple walking in park
Investing Articles

3 UK shares to consider as a long-term investment for retirement

Our writer identifies three UK shares with long-term growth potential he believes investors should think about holding until retirement and…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

Could this beaten-down FTSE 250 stock be on the cusp of a recovery in 2025?

After this FTSE 250 financial services stock lost another 24% of its value in 2024, Andrew Mackie sees the potential…

Read more »

The Milky Way at night, over Porthgwarra beach in Cornwall
Investing Articles

Warren Buffett says make passive income while sleeping! Here’s my plan to do so

Billionaire Warren Buffett has said many wise things over the past half a century, including a thing or two about…

Read more »

Investing Articles

£5,000 invested in this FTSE 250 company 5 years ago is now worth over £24,000

Stephen Wright looks at how a FTSE 250 food stock has more than quadrupled over the last five years –…

Read more »